Navigation Links
Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
Date:6/22/2011

CAMBRIDGE, England, June 21, 2011 /PRNewswire/ --


 

Crescendo Biologics Limited (Crescendo) today announces the appointment of Matthew Roe as Chief Business Officer. Matthew joins Crescendo from Genzyme Corporation where he was Senior Director, Business Development & Licensing.

During a 23-year career at Genzyme, Matthew was active in licensing, alliance management, acquisition, divestment, and sales and marketing, and saw the corporation develop from an entrepreneurial start-up to a leading multi-national biotechnology company. He negotiated and managed multiple agreements for drug delivery technologies in the USA, Europe and Japan and was also a core team member on the divestment of Genzyme's Pharmaceuticals business.

Mike Romanos, CEO of Crescendo said: "Matthew's track record in business development speaks for itself. He has an exceptional depth of experience in business strategy and in implementing agreements across multiple territories. I look forward to working with him as we build on the significant advances we have made at Crescendo and position the Company to deliver real value from its world class, proprietary technology platforms."

Matthew Roe, CBO of Crescendo said: "The monoclonal antibody market is rapidly growing and continues to be a major focus for the pharma industry. Companies are searching for new platforms and approaches, particularly in the area of antibody fragments. Crescendo's technology platform, IP and insight create a strong foundation from which to make a significant impact in the field and I am delighted to be joining the Company's management team as it seeks to grow to become a leader in next-generation antibody therapeutics."

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.

Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The Company has raised £4.5 million in seed funding from leading life sciences investors, Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.  http://www.crescendobiologics.com

Contacts

Mike Romanos/Amanda Bettison
Crescendo Biologics
Tel: +44(0)1223-497140
Email: mromanos/abettison@crescendobiologics.com

Chris Gardner
Citigate Dewe Rogerson
Tel: +44(0)207-638-9571
Email: chris.gardner@citigatedr.co.uk



'/>"/>
SOURCE Crescendo Biologics Limited
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Crescendo Biologics Announces First Triple Knockout Mouse
2. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
3. Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi
4. Reportlinker Adds Whats Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015
5. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
6. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities and Pelvis Market
7. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
8. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
9. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Reportlinker Adds Immunogenicity to Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit ... are researched, developed, marketed and made accessible to patients around ... Open had named the publication of the Good ... The publication is also featured as one of BMJ ... the last year that are most frequently read. ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today announced ... Portland, Oregon -based community care organization ... population health analytics, quality reporting and care management ... strengthen its team of quality managers, analysts and ... the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... CRUZ, Calif. , Feb. 11, 2016  Dovetail ... applications to its beta program for a planned metagenomic ... will present the company,s metagenomic genome assembly method in ... Advances in Genome Biology & Technology conference in ... assembly of these highly complex datasets is difficult. Using ...
(Date:2/11/2016)... BioInformant announces the February 2016 release of its ... and Technologies – Market Size, Segments, Trends, and Projections ... The first and only market research firm ... more than a decade of historical information on all ... type. This powerful 175 page global strategic report contains ...
Breaking Biology Technology:
(Date:1/28/2016)... Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), ... for its second quarter ended December 31, 2015. ... quarter of fiscal 2016 increased 2 percent compared to the comparable ... quarter of fiscal 2016 was $35.0 million, or $0.93 per diluted ... net income for the first quarter of fiscal 2016 grew 9 ...
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):